Caitlin John’s AbbVie ABBV Stock Holding History

Caitlin John’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,100	Closed	-$195K	–	130
2024 Q4	$195K	Buy	+1,100	New	+$202K	0.13%	132

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Caitlin John's ABBV Position: Q1 2026 in Review

Caitlin John increased its AbbVie (ABBV) stake by 6.4% in Q1 2026, buying an estimated $2K and bringing the position to 149 shares worth $32.3K. The position accounts for 0.02% of the portfolio, ranked #359.

Caitlin John first reported a position in ABBV in Q4 2023 and has held it in 8 quarters since. The position peaked at $33.3K in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Caitlin John held 149 shares of AbbVie worth $32.3K as of Q1 2026.
Caitlin John bought 9 AbbVie shares in Q1 2026, an estimated $2K.
AbbVie made up 0.02% of Caitlin John's portfolio in Q1 2026, its #359 holding.
Caitlin John first reported a position in AbbVie in Q4 2023 and has held it in 8 quarters since.
Caitlin John's AbbVie position peaked at $33.3K in Q3 2025.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Caitlin John's 13F filing for Q1 2026, filed 13 May 2026.